Published in Cancer Treat Rev on December 01, 2000
Breast cancer metastasis to the central nervous system. Am J Pathol (2005) 3.30
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx (2005) 2.44
Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol (2004) 1.71
Expression of matrix metalloproteinases and their tissue inhibitor during viral encephalitis. J Virol (2005) 1.10
Examination of blood-brain barrier (BBB) integrity in a mouse brain tumor model. J Neurooncol (2012) 0.94
Irradiation of rat brain reduces P-glycoprotein expression and function. Br J Cancer (2007) 0.91
Role of ABC transporters in the pathogenesis of Alzheimer's disease. ACS Chem Neurosci (2012) 0.90
Transporters at CNS barrier sites: obstacles or opportunities for drug delivery? Curr Pharm Des (2014) 0.88
Relationship between HER-2 overexpression and brain metastasis in esophageal cancer patients. World J Gastrointest Oncol (2012) 0.86
Mechanisms of the penetration of blood-borne substances into the brain. Curr Neuropharmacol (2009) 0.86
Quantitative evaluation of monocyte transmigration into the brain following chemical opening of the blood-brain barrier in mice. Brain Res (2006) 0.86
P-glycoprotein function at the blood-brain barrier: effects of age and gender. Mol Imaging Biol (2012) 0.85
Reproducibility of quantitative (R)-[11C]verapamil studies. EJNMMI Res (2012) 0.85
Targeting the neurovascular unit for treatment of neurological disorders. Pharmacol Ther (2010) 0.85
Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. Eur Radiol (2009) 0.85
Glioma stem cells and immunotherapy for the treatment of malignant gliomas. ISRN Oncol (2013) 0.84
Role of IFN-γ and LPS on neuron/glial co-cultures infected by Neospora caninum. Front Cell Neurosci (2014) 0.82
Blood-brain barrier P-glycoprotein function in healthy subjects and Alzheimer's disease patients: effect of polymorphisms in the ABCB1 gene. EJNMMI Res (2012) 0.82
Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis. J Biol Chem (2015) 0.82
Expression and clinical significance of multidrug resistance proteins in brain tumors. J Exp Clin Cancer Res (2010) 0.82
Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1. Br J Cancer (2011) 0.81
Brain metastases from colorectal cancer: microenvironment and molecular mechanisms. Int J Mol Sci (2012) 0.80
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget (2016) 0.79
New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence. Pharmacol Ther (2009) 0.78
Dietary blueberry supplementation affects growth but not vascularization of neural transplants. J Cereb Blood Flow Metab (2008) 0.78
Preparation and biocompatibility study of in situ forming polymer implants in rat brains. J Mater Sci Mater Med (2011) 0.78
Pharmacotherapy for adults with tumors of the central nervous system. Pharmacol Ther (2008) 0.78
Gliadel for brain metastasis. Surg Neurol Int (2013) 0.77
Monocytes-derived macrophages mediated stable expression of human brain-derived neurotrophic factor, a novel therapeutic strategy for neuroAIDS. PLoS One (2014) 0.77
No evidence for additional blood-brain barrier P-glycoprotein dysfunction in Alzheimer's disease patients with microbleeds. J Cereb Blood Flow Metab (2012) 0.77
Evaluating Changes to Blood-Brain Barrier Integrity in Brain Metastasis over Time and after Radiation Treatment. Transl Oncol (2016) 0.76
Delivery of a peptide-drug conjugate targeting the blood brain barrier improved the efficacy of paclitaxel against glioma. Oncotarget (2016) 0.75
Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Transl Res (2015) 0.75
Corrupting the DNA damage response: a critical role for Rad52 in tumor cell survival. Aging (Albany NY) (2017) 0.75
Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med (2000) 6.34
Mycobacterium ulcerans infection. Lancet (1999) 4.52
Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther (2010) 3.42
Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A (1994) 2.52
No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol (2001) 2.31
Increased cancer risk after liver transplantation: a population-based study. J Hepatol (2001) 2.25
Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability. Eur Heart J (1995) 2.21
Procalcitonin behaves as a fast responding acute phase protein in vivo and in vitro. Crit Care Med (2000) 2.19
Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med (2001) 2.18
Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res (1993) 1.99
Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol (2001) 1.92
Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol (2000) 1.89
Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res (1993) 1.81
Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1987) 1.81
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol (1992) 1.62
Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol (2000) 1.62
The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev (2004) 1.60
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. Eur J Cancer (1997) 1.52
Susceptibility to development of Mycobacterium ulcerans disease: review of possible risk factors. Trop Med Int Health (2001) 1.51
Mycobacterium ulcerans infection in Ashanti region, Ghana. Trans R Soc Trop Med Hyg (1990) 1.48
Excessively high cell proliferation in sigmoid colon after an oral purge with anthraquinone glycosides. J Natl Cancer Inst (1995) 1.43
Syndrome X in testicular-cancer survivors. Lancet (2001) 1.43
Combination therapy with cisplatin: modulation of activity and tumour sensitivity. Clin Oncol (R Coll Radiol) (1992) 1.43
Imaging of soft-tissue tumors using L-3-[iodine-123]iodo-alpha-methyl-tyrosine single photon emission computed tomography: comparison with proliferative and mitotic activity, cellularity, and vascularity. Clin Cancer Res (2000) 1.42
5-Fluorouracil/leucovorin/interferon alpha-2a in patients with advanced colorectal cancer. Effects of maintenance therapy on remission duration. Cancer (1995) 1.40
Endodermal sinus tumor of the ovary during pregnancy: a case report. Am J Obstet Gynecol (1991) 1.40
[Good results with liver resection for colorectal liver metastases]. Ned Tijdschr Geneeskd (1995) 1.40
[The biopsying of at least 5 mediastinal lymph node stations for presurgical staging in patients with a non-small-cell lung carcinoma]. Ned Tijdschr Geneeskd (2004) 1.39
[Carboplatin in the treatment of ovarian carcinoma; as effective and less toxic in comparison with cisplatin]. Ned Tijdschr Geneeskd (1991) 1.38
A 17-yr old boy with productive cough and progressive dyspnoea. Eur Respir J (2000) 1.37
Review article: anthranoid laxatives and their potential carcinogenic effects. Aliment Pharmacol Ther (1999) 1.34
11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol (2003) 1.34
Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res (1990) 1.33
Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Am J Cardiol (1996) 1.33
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer (1996) 1.32
Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med (1995) 1.30
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages. Cancer Res (2001) 1.28
Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol (1998) 1.28
Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma. Int J Cancer (1999) 1.27
Modulation of cis-diamminedichloroplatinum(II) resistance: a review. Br J Cancer (1992) 1.25
Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res (1992) 1.21
Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res (1988) 1.21
Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood (1995) 1.19
Detection of unknown occult primary tumors using positron emission tomography. Cancer (1998) 1.18
ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol (1999) 1.17
Familial testicular cancer in a single-centre population. Eur J Cancer (1999) 1.17
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 1.16
Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood (1994) 1.16
Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst (1989) 1.16
Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma. J Cancer Res Clin Oncol (1989) 1.16
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res (1992) 1.14
The distribution of drug-efflux pumps, P-gp, BCRP, MRP1 and MRP2, in the normal blood-testis barrier and in primary testicular tumours. Eur J Cancer (2004) 1.14
Bacterial counts in carious dentine under restorations: 2-year in vivo effects. Caries Res (1999) 1.13
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet (2001) 1.12
Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. Br J Cancer (1996) 1.12
Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med (1996) 1.11
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer (1998) 1.11
TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat (2009) 1.11
Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol (1995) 1.10
High performance liquid chromatographic profiling of tryptophan and related indoles in body fluids and tissues of carcinoid patients. Clin Chim Acta (1993) 1.09
Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. Cancer Res (1988) 1.08
Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc Natl Acad Sci U S A (1992) 1.08
Diffusion capacity and haemodynamics in primary and chronic thromboembolic pulmonary hypertension. Eur Respir J (2000) 1.07
Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer. Br J Cancer (2000) 1.07
Cisplatin-induced DNA-platination in experimental dorsal root ganglia neuronopathy. Neurotoxicology (1999) 1.05
[Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor]. Ned Tijdschr Geneeskd (2003) 1.04
Combined in vitro modulation of adriamycin resistance. Int J Cancer (1991) 1.04
Clinical chemistry of serotonin and metabolites. J Chromatogr B Biomed Sci Appl (2000) 1.03
Quantitative myocardial mapping of perfusion and metabolism using parametric polar map displays in cardiac PET. J Nucl Med (1995) 1.03
Drug development, radiolabelled drugs and PET. Ann Med (1999) 1.03
Sentence comprehension and word repetition: a positron emission tomography investigation. Psychophysiology (1999) 1.03
Comparison of L-[1-11C]methionine and L-methyl-[11C]methionine for measuring in vivo protein synthesis rates with PET. J Nucl Med (1988) 1.02
Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet (1991) 1.02
Visualization of prostate cancer with 11C-choline positron emission tomography. Eur Urol (2002) 1.02
Superior vena cava obstruction caused by radiation induced venous fibrosis. Thorax (2000) 1.02
Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res (1998) 1.02
An improved method for the cyclotron production of 13N-labelled ammonia. Int J Appl Radiat Isot (1975) 1.01
Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer (1998) 1.01
Ophthalmic toxicity following paclitaxel infusion. Ann Oncol (1997) 1.00
Resistance-associated factors in human small-cell lung-carcinoma GLC4 sub-lines with increasing adriamycin resistance. Int J Cancer (1995) 1.00
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. J Clin Oncol (1999) 1.00
Selection of a subpopulation with fewer DNA topoisomerase II alpha gene copies in a doxorubicin-resistant cell line panel. Br J Cancer (1996) 1.00
Long-term follow-up of cardiovascular risk factors in patients given chemotherapy for disseminated nonseminomatous testicular cancer. Ann Intern Med (1992) 1.00
Influence of P-glycoprotein on brain uptake of [18F]MPPF in rats. Eur J Pharmacol (2000) 0.99
Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem (2000) 0.99